Detailed Information on Publication Record
2019
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
BRUGGEMANN, M., M. KOTROVA, H. KNECHT, J. BARTRAM, M. BOUDJOGRHA et. al.Basic information
Original name
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
Authors
BRUGGEMANN, M. (276 Germany), M. KOTROVA (203 Czech Republic), H. KNECHT (276 Germany), J. BARTRAM (826 United Kingdom of Great Britain and Northern Ireland), M. BOUDJOGRHA (250 France), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), G. FAZIO (380 Italy), E. FRONKOVA (203 Czech Republic), M. GIRAUD (250 France), A. GRIONI (250 France), J. HANCOCK (826 United Kingdom of Great Britain and Northern Ireland), D. HERRMANN (276 Germany), C. JIMENEZ (724 Spain), Adam KREJČÍ (203 Czech Republic, belonging to the institution), J. MOPPETT (826 United Kingdom of Great Britain and Northern Ireland), Tomáš REIGL (203 Czech Republic, belonging to the institution), M. SALSON (250 France), B. SCHEIJEN (528 Netherlands), M. SCHWARZ (276 Germany), S. SONGIA (380 Italy), M. SVATON (203 Czech Republic), J.J.M. VAN DONGEN (528 Netherlands), P. VILLARESE (250 France), S. WAKEMAN (826 United Kingdom of Great Britain and Northern Ireland), G. WRIGHT (826 United Kingdom of Great Britain and Northern Ireland), G. CAZZANIGA (380 Italy), F. DAVI (250 France), R. GARCIA-SANZ (724 Spain), D. GONZALEZ (372 Ireland), P.J.T.A. GROENEN (528 Netherlands), M. HUMMEL (372 Ireland), E.A. MACINTYRE (250 France), K. STAMATOPOULOS (300 Greece), C. POTT (276 Germany), J. TRKA (203 Czech Republic), Nikos DARZENTAS (300 Greece, guarantor, belonging to the institution) and A.W. LANGERAK (528 Netherlands)
Edition
Leukemia, London, Nature Publishing Group, 2019, 0887-6924
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.665
RIV identification code
RIV/00216224:14740/19:00108540
Organization unit
Central European Institute of Technology
UT WoS
000484399300009
Keywords in English
MINIMAL RESIDUAL DISEASE; TIME QUANTITATIVE PCR; CONCERTED ACTION; BONE-MARROW; REARRANGEMENTS; RELAPSE; HEAVY; QUANTIFICATION; CHILDREN; PRIMERS
Tags
Tags
International impact, Reviewed
Změněno: 24/10/2024 16:30, Ing. Marie Švancarová
Abstract
V originále
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0-14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0-14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.
Links
LM2015085, research and development project |
| ||
NV16-34272A, research and development project |
| ||
90091, large research infrastructures |
|